Complement Component C9 Antibody (X197) - Azide Free

• Reactivity: Hu
• Applications: WB, ELISA, Flow, Func, IHC, IP
• Clone: X197
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide Free
• Concentration: 0.1 mg/ml

Complement Component C9 Antibody (X197) - Azide Free Summary

• Description: Novus Biologicals Mouse Complement Component C9 Antibody (X197) - Azide Free (NBP1-52797) is a monoclonal antibody validated for use in IHC, WB, Flow and IP. Anti-Complement Component C9 Antibody: Cited in 3 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Human C9 is used for the immunogen. The exact sequence is proprietary.
• Specificity: This product is useful for detecting Component C9. This is also specific for inhibition of C9 binding to C5b-8.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: C9
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:10-1:1000
  • Functional
  • Immunoassay
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Frozen 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation
  • Western Blot 1:100-1:2000
• Application Notes: The antibody can be used for immuno assays, flow cytometry and Western blotting.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 0.2 um filtered solution in PBS and 0.1% BSA
• Preservative: No Preservative
• Concentration: 0.1 mg/ml
• Purity: Protein A or G purified

Alternate Names for Complement Component C9 Antibody (X197) - Azide Free

• complement component 9
• Complement Component C9

Background

Human C9 is a soluble glycoprotein of 61 kD. It is the last component in the assembly of the membrane attack complex (MAC). When the complement is activated on target membranes, multiple copies of C9 bind to the C5b-8 complex and assemble the barrel-shaped pore which causes cell lysis. The conformation of C9 changes from globular to a tubular form. The binding of C9 to C5b-8 plays a key role in the function of C9.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Complement Component C9 Antibody (NBP1-52797)(3)

Publications using NBP1-52797

• Lo Casto A, Spataro R, Purpura P, La Bella V. Unilateral laryngeal and hypoglossal paralysis (Tapia's syndrome) in a patient with an inflammatory pseudotumor of the neck. Clinical neurology and neurosurgery 2014-02-20 [PMID: 23265562]
• Filella M, Williams PA. Antimony biomethylation in culture media revisited in the light of solubility and chemical speciation considerations. 2010-12-21 [PMID: 20549617]
• Hatanaka, M et al. Analysis of C5b-8 binding sites in the C9 molecule using monoclonal antibodies: participation of two separate epitopes of C9 in C5b-8 binding. Mol Immunol , 29: 911. 1992-01-01 [PMID: 1378934]

Bioinformatics

• Gene Symbol: C9
• Entrez:
  • 735(Human)